Background Indacaterol is a long-acting inhaled β2-agonist (LABA) for the treatment of
chronic obstructive pulmonary disease (COPD). In previous studies, indacaterol provided 24 …

Efficacy of a new once-daily long-acting inhaled 2-agonist indacaterol versus twice-daily
formoterol in COPD | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …

The authors thank the patients who took part and the staff at the participating clinical centres.
Sarah Filcek (ACUMED) and David Young (Novartis) assisted in the preparation of the …

Background Indacaterol is a long-acting inhaled beta (2)-agonist (LABA) for the treatment of
chronic obstructive pulmonary disease (COPD). In previous studies, indacaterol provided 24 …

BACKGROUND: Indacaterol is a long-acting inhaled beta (2)-agonist (LABA) for the
treatment of chronic obstructive pulmonary disease (COPD). In previous studies, indacaterol …

Background Indacaterol is a long-acting inhaled b2-agonist (LABA) for the treatment of
chronic obstructive pulmonary disease (COPD). In previous studies, indacaterol provided 24 …

Background Indacaterol is a long-acting inhaled β 2-agonist (LABA) for the treatment of
chronic obstructive pulmonary disease (COPD). In previous studies, indacaterol provided 24 …

Background Indacaterol is a long-acting inhaled beta (2)-agonist (LABA) for the treatment of
chronic obstructive pulmonary disease (COPD). In previous studies, indacaterol provided 24 …

Background Indacaterol is a long-acting inhaled b2-agonist (LABA) for the treatment of
chronic obstructive pulmonary disease (COPD). In previous studies, indacaterol provided 24 …

Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily
formoterol in COPD CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …